Lead Product(s) : Phenazon,Lidocaine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $15.9 million
Deal Type : Acquisition
Lupin announces acquisition of UK-Based Renascience Pharma for GBP 12.3 mn
Details : Through the acquisition, Lupin will leverage Renascience key products, which includes Otigo (phenazone/lidocaine HCl) for pain due to acute otitis media.
Product Name : Otigo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 03, 2025
Lead Product(s) : Phenazon,Lidocaine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $15.9 million
Deal Type : Acquisition
Reset All
